US equities
|
NVDA
$238.91
▲+2.12%
SPCX
$168.14
▲+5.78%
MU
$1,060.33
▼-1.35%
TSLA
$380.46
▲+2.66%
MSFT
$527.21
▲+1.87%
SNDK
$1,692.51
▼-1.60%
INTC
$116.72
▼-2.19%
META
$742.81
▲+2.02%
NVDA
$238.91
▲+2.12%
SPCX
$168.14
▲+5.78%
MU
$1,060.33
▼-1.35%
TSLA
$380.46
▲+2.66%
MSFT
$527.21
▲+1.87%
SNDK
$1,692.51
▼-1.60%
INTC
$116.72
▼-2.19%
META
$742.81
▲+2.02%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tevogen Inc. - Warrant
(NQ:
TVGNW
)
0.0597
-0.0016 (-2.61%)
Delayed Quote
Updated: 10:47 AM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Tevogen Inc. - Warrant
< Previous
1
2
3
4
5
6
7
Next >
Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Listing Social Engagement Event
June 06, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2
June 06, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio Reports First Quarter 2024 Financial Results
May 29, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives
May 16, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives
May 10, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives
May 01, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments
April 26, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers
April 11, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development
April 03, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price
March 28, 2024
From
Tevogen Bio Inc
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
